| Metric | Value (₹ Cr) | vs Q4 FY25 |
|---|---|---|
| Revenue | 669.80 | 11.2% |
| Total Income | 697.90 | 11.1% |
| Expenditure | 516.80 | 8.8% |
| PBT | 181.10 | 18.1% |
| Net Profit | 134.00 | 13.8% |
| OPM | 28.71% | 0.66pp |
| NPM | 19.20% | 5.55pp |
| EPS | 15.88 | 14.5% |
Dr. Lal PathLabs Q1 FY26 Results: Revenue Up 11.3%, PAT Up 24.3%
31 Jul 2025 · 31 Jul 2025, 01:46 pm
Summary
Dr. Lal PathLabs Limited, a leading diagnostic and related healthcare service provider, has announced their financial results for the quarter ended June 30, 2025. The company reported an 11.3% increase in revenue, a 13.1% increase in EBITDA with a margin of 28.7%, and a 24.3% increase in PAT with a margin of 20.0%. The company also declared an interim dividend of Rs. 6 per share for Q1 FY26.
Key Highlights
- 1
Q1 FY26 Revenue increased by 11.3%
- 2
EBITDA increased by 13.1% with a margin of 28.7%
- 3
PAT increased by 24.3% with a margin of 20.0%
- 4
Interim Dividend of Rs. 6 per share for Q1 FY26
- 5
As on March 31, 2025, the company has 298 clinical laboratories, 6,607 Patient Service Centers (PSCs), and 12,365 Pick-up Points (PUPs)
Management Comments
Dr. Lal PathLabs Limited
Through its’ integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.
Informational and educational content only. Not investment advice.